SILENCE THERAPEUTICS, INC.

Harpreet Gill discusses decentralized clinical trials' progress. Paige Bingham focuses on improving clinical research for patients. Damien Bailly emphasizes partnerships for patient access to medicines. Yvonne Greenstreet advances RNAi therapeutics. Craig Tooman navigates biotech funding challenges. Ken Keller transforms Daiichi Sankyo into oncology. Jan van de Winkel envisions Genmab as a commercial driver. Rafaat Rahmani's journey from poverty to life sciences. Noam Solomon uses AI for cancer treatments. Margaret Keegan aims to lead in drug development.

New Amsterdam's Phase III TANDEM trial met co-primary endpoints, showing a 48.6% reduction in LDL-C with obicetrapib-ezetimibe combination, supporting regulatory filings for HeFH and ASCVD patients.

Zerlasiran, a novel siRNA, demonstrated sustained reductions in lipoprotein(a) levels exceeding 80% with infrequent dosing in the Phase II ALPACAR-360 trial. The study, presented at the AHA’s Scientific Sessions 2024, highlighted zerlasiran's efficacy, safety, and tolerability, supporting its potential as a long-term treatment for high lipoprotein(a) patients at risk of ASCVD events.

Zerlasiran, an siRNA, reduced time-averaged Lp(a) concentrations by over 80% in a 36-week trial, marking the first time such reduction has been reported for an siRNA therapy. The study suggests that each successive dose of zerlasiran extends the duration of Lp(a) reduction, informing future phase 3 trials and potentially optimal dosing strategies for other siRNA therapies.

Eli Lilly's muvalaplin and Silence Therapeutics' zerlasiran, both targeting lipoprotein(a), showed promising results in Phase II trials, with reductions of up to 86% in Lp(a) levels. These results were presented at the American Heart Association conference and published in JAMA.

FDA rejects Astellas' label change for eye drug Izervay; Cytokinetics and Bayer partner for heart drug aficamten in Japan; Eli Lilly's muvalaplin and Silence Therapeutics' zerlasiran show promise in reducing lipoprotein(a) levels; former NCI director Ned Sharpless launches biotech Jupiter; Merck's new Keytruda formulation proves effective; global drug access in low- and middle-income countries remains limited; AHA conference highlights obesity drugs, blood pressure management, and novel treatments for heart conditions.

Silence Therapeutics presented Phase 2 ALPACAR-360 study data on zerlasiran, showing >80% mean time-averaged placebo-adjusted reductions in Lp(a) concentrations over 36 weeks, with maximum reductions exceeding 90%. No safety concerns emerged, and reductions persisted at 60 weeks post-initial administration.

Zerlasiran, an siRNA drug, reduced lipoprotein(a) levels by over 80% in a 36-week trial, suggesting potential for preventing heart disease in those with high Lp(a). The trial, presented at the American Heart Association’s Scientific Sessions 2024, showed minimal side effects and persistent reductions up to 60 weeks post-administration.

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Akero Therapeutics (AKRO) on Nov 15, setting a $46.00 price target, citing promising Phase 2b HARMONY study results showing efruxifermin's anti-fibrotic effect in F2/3 MASH patients. Ulz anticipates upcoming SYMMETRY study results in F4 MASH as a key catalyst. Evercore ISI also assigned a Buy rating with a $38.00 price target on Nov 11.

DelveInsight's Alpha Thalassemia Market Insights report forecasts significant market growth (2020-2034) driven by rising prevalence, genetic research advancements, and emerging therapies from companies like Agios Pharmaceuticals, Forma Therapeutics, and Novartis Pharmaceuticals.